Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues
Reexamination Certificate
2003-10-22
2008-11-04
Huynh, Phuong (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
C530S350000, C530S387300, C530S399000
Reexamination Certificate
active
07446168
ABSTRACT:
The present invention is directed to novel polypeptides designated herein as EG-VEGF and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Also provided herein are methods of screening for modulators of EG-VEGF. Furthermore, methods and related methods of treatment are described herein which pertain to regulating cellular proliferation and chemotaxis.
REFERENCES:
patent: 4946778 (1990-08-01), Ladner et al.
patent: 5858682 (1999-01-01), Gruenwald et al.
patent: 6132729 (2000-10-01), Thorpe et al.
patent: 6180370 (2001-01-01), Queen et al.
patent: 6485938 (2002-11-01), Sheppard et al.
patent: 7119177 (2006-10-01), Goddard et al.
patent: 2003/0054404 (2003-03-01), Ashkenazi et al.
patent: 0 834 563 (1998-04-01), None
patent: 1 033 401 (2000-09-01), None
patent: 0 607 054 (2002-11-01), None
patent: WO 97/07198 (1997-02-01), None
patent: WO 98/39448 (1998-09-01), None
patent: WO 98/42741 (1998-10-01), None
patent: WO 99/06550 (1999-02-01), None
patent: WO 99/46375 (1999-09-01), None
patent: WO 99/53040 (1999-10-01), None
patent: WO 99/63083 (1999-12-01), None
patent: WO 99/63088 (1999-12-01), None
patent: WO 00/08145 (2000-02-01), None
patent: WO 00/52022 (2000-09-01), None
patent: WO 00/53753 (2000-09-01), None
patent: WO 00/70049 (2000-11-01), None
patent: WO 00/73454 (2000-12-01), None
patent: WO 00/75327 (2000-12-01), None
patent: WO 01/36465 (2001-05-01), None
patent: WO 01/40466 (2001-06-01), None
patent: WO 01/57190 (2001-08-01), None
Bullock et al, Mol Pharmacol 65: 582-588, 2004.
Negri et al, British J of Pharmacology 146: 625-632, 2005.
Carmeliet et al, Nature 412: 868-869, Aug. 2001.
Rieger et al, Glossary of Genetics: p. 16, 1991.
Aird, W.C. et al., 1997,J. Cell Biol. 138:1117-1124 “Vascular bed-specific expression of an endothelial cell gene is programmed by the tissue microenvironment”.
Aravind, L. and Koonin, E.V., 1998,Curr. Biol. 8:477-478 “A colipase fold in the carboxy-terminal domain of the Wnt antagonists- the Dickkopfs”.
Arbiser, J.L. et al., 1997,Proc. Natl. Acad. Sci. USA, 94:861-866 “Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways”.
Attwood et al., Oct. 2000,Science290(5491): 417-473 “The babel of bioinformatics”.
Basset, D.L., 1943,Am. J. Anat., 73:251-278 “The changes in the vascular pattern of the ovary of the albino rat during the estrous cycle”.
Boisbouvier, J. et al., 1998,J. Mol. Biol. 283: 205-219 “A structural homologue of colipase in black mamba venom revealed by NMR floating disulphide bridge analysis”.
Carmeliet, P., 2000,Nature Medicine, 6:389-395 “Mechanisms of angiogenesis and arteriogenesis”.
Collin, O. & Bergh A., 1996,Int. J. Androl., 19:221-228 “Leydig cells secrete factors which increase vascular permeability and endothelial cell proliferation”.
Dellian, M. et al., 1996,Am. J. Pathology, 149:59-71 “Quantitation and physiological caracterization of angiogenic vessels in mice: effect of basic fibroblast growth factor, vascular endothelial growth factor/vascular permeability factor, and host microenvironment”.
Esser, S. et al., 1998,J. Cell. Biol., 140:947-959 “Vascular endothelial growth factor induces endothelial fenestrations in vitro” (1998).
Ferrara, N. & Alitalo, 1999,Nature Medicine, 5:1359-1364 “K. Clinical applications of angiogenic growth factors and their inhibitors”.
Ferrara, N. et al., 1998,Nature Medicine, 4:336-340 “Vascular endothelial growth factor is essential for corpus luteum angiogenesis”.
Ferrara, N., 2000,Curr. Opin. Biotech11: 617-624 “VEGF: an update on biological and therapeutic aspects”.
Fogarty et al., 2002,The Scientist, 16(16):33.
Fraser et al., 2000,Endocrinology, 141(3):995-1000 “Suppression of LuteaL Angiogenesis in the Primate after Neutralization of Vascular Endothelial Growth Factor”.
Gille, H. et al., 2001,J. Biol. Chem., 276:3222-3230 “Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants”.
Glinka, A. et al., 1998,Nature, 391:357-362 “Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction”.
Goldziher, J.W. & Green, J.A., 1962,J. Clin: Endocrinol. Meta. 22:325-332 “The polycystic ovary. I. Clinical and histologic features”.
Gospodarowitcz et al., 1984,J. Cell. Biol., 99:947-961 “Comparison of the Ability of Basement Membranes Produced by Corneal Endothelial and Mouse-derived Endodermal PF-HR-9 Cells to Support the Proliferation and Differentiation of Bovine Kidney Tubule Epithelial Cells in Vitro”.
Joubert, F.J. & Strydom, D.J., 1980,Hoppe-Seylers Zeitschrift fur Physiologische Chemie, 361:1787-1794 “Snake venom. The amino acid sequence of protein A from Dendroaspis polylepis polytepis (black mamba) veno”.
Klagsburn, M., 1992,Semin. Cancer Biol., 3:81-87 “Mediators of angiogenesis: the biological significance of basic fibroblast growth factor (bFGF)-heparin and heparan sulfate interactions”.
Krupnik, V.E. et al., 1999,Gene, 238:301-313 “Functional and structural diversity of the human Dickkopf gene family”.
LeCouter, J. et al., 2001,Nature, 412(6850):877-884 “Identification of an angiogenic mitogen selective for endocrine gland endothelium”.
Leung et al., 1989,Science, 246:1306-1309 “Vascular endothelial growth factor is a secreted aniogenic mitogen”.
Lind et al., 1995,APMIS, 103:140-146 “Chemotaxis of bumna osteoblasts”.
Melton, D. A. et al., 1984,Nucleic Acids Res., 12:7035-7056 “Efficient in vitro synthesis of biologically active RNA and RNA hybridization probes from plasmids containing a bacteriophage SP6 promoter”.
Mesiano et al., 1993,J. Clin. Endocrinol. Metab. 76:968-976 “Mitogenic Action, Regulation, and Localization of Insulin-Like Growth Factors in the Human Fetal Adrenal Gland”.
Mueller et al., 1995,Eur. J. Immunol., 25:1744-1746 “Cloning of ATAC, an activation-induced chemokine-related molecule exclusively expressed in CD7+ T lunphocytes”.
Ngo et al., in The Protein Folding Problem and Tertiary Structure Prediction, 1994, Merz et al., (ed.), Birkhauser, Boston, MA, 443 and 492-495.
Palade, G.E. et al.,1979,Acta Physiol. Scand. Suppl., 463:11-32 “Structural aspects of the permeability of the microvascular endothelium”.
Petterson, A. et al., 2000,Lab. Invest. 80:99-115 “Heterogeneity of the angiogenic response induced in different normal tissues by vascular permeability factor/vascular endothelial growth factor”.
Phillips, H.S. et al., 1990,Science250:290-294 “Widespread expression of BDNF but not NT3 by target areas of basal forebrain cholinergic neurons”.
Phillips et al., 1990,Endocrinology, 127:965-967 “Vascular endothelial growth factor is expressed in rat corpus luteum”.
Ravindranath et al., 1992,Endocrinology, 131(1):254-260 “Vascular Endothelial Growth Factor Messenger Ribonucleic Acid Expression in the Primate Ovary”.
Roberts and Palade, 1997,Cancer Res., 57:765-772 “Host Microvascularture Influence on Tumor Vascular Morphology and Endothelial Gene Expression”.
Ryan A.M. et al., 1999,Toxicol. Pathol. 27:78-86 “Preclinical safety evaluation of rhuMAbVEGF, an Antiangiogenic humanized monoclonal antibody”.
Schweitz et al., 1999,FEBS Lett. 461:183-188 “MIT(1), a black mamba toxin with a new and highly potent activity on intestinal contraction”.
Seme
Ferrara Napoleone
Watanabe Colin
Wood William I.
Genentech Inc.
Huynh Phuong
Merchant & Gould P.C.
LandOfFree
EG-VEGF nucleic acids and polypeptides and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with EG-VEGF nucleic acids and polypeptides and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and EG-VEGF nucleic acids and polypeptides and methods of use will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4050943